This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS effectively delays and blocks the acetylation process of INH in the body, can maintain a higher and longer INH concentration in the blood, and reduces toxicity to the liver. It enhances the bactericidal effect of drugs and delays the development of bacterial resistance. In combined treatment with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than that of INH and the incidence of adverse reactions is lower. Animal experiments have shown that for artificially infected mice, the anti-tuberculosis efficacy of this product is about 5 times that of INH.

This product is a chemical compound of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS delays and blocks the acetylation process of INH in the body, can maintain a higher and longer INH concentration in the blood, and reduce toxicity to the liver. Clinically confirmed, this product has significantly better anti-tuberculosis efficacy than INH, and the incidence of adverse reactions is lower than INH. Animal experiments show that the anti-tuberculosis efficacy of this product is about 5 times that of INH.

This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS delays and blocks the acetylation process of INH in the body, maintains a higher and longer INH concentration and reduces toxicity to the liver. It enhances the bactericidal effect and delays the development of bacterial resistance. In combined treatment with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than that of INH, and the incidence of adverse reactions is lower than that of INH. Animal experiments have shown that for artificially infected mice, the anti-tuberculosis efficacy of this product is about 5 times that of INH.

Not yet clear

This product is a mucolytic agent that can increase the secretion of serous glands in the respiratory mucosa and reduce the secretion of mucous glands, thereby reducing sputum viscosity, promoting the secretion of pulmonary surfactant, increasing bronchial ciliary movement, and making sputum easier to cough up.